We demonstrated that TGF-β and Bcl-2 had potential prognostic values in prostate cancer patients (Figure 6A, C, S7A-C) and that Bcl-2 inhibitor, ABT-199, blocked DTX resistance in vitro mediated by TGF-β (Figure 5E) and acetylated KLF5 mediated DTX resistance in vitro (Figure 3F), which warrant in vivo studies to test TGF-β receptor 1 inhibitor (e.g., SB-505124) and Bcl-2 inhibitor (e.g., ABT-199) for their therapeutic value in overcoming DTX resistance. This evidence concerns the gene BCL2 and prostate cancer.